We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SPRO Spero Therapeutics Inc

0.00 (0.0%)
Pre Market
Last Updated: 07:36:45
Delayed by 15 minutes


Draw Mode:

Volume 10
Bid Price 1.23
Ask Price 1.29
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Spero Therapeutics Inc SPRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.26 07:36:45
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
3 10 - 0.99 - 2.04
Last Trade Time Type Quantity Stock Price Currency
08:03:28 6 $ 1.26 USD

Spero Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
66.78M 53.00M - 53.51M -46.42M -0.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Spero Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SPRO Message Board. Create One! See More Posts on SPRO Message Board See More Message Board Posts

Historical SPRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.141.311.141.25138,1550.1210.53%
1 Month1.051.311.051.17165,6960.2120.0%
3 Months1.291.320.991.17171,957-0.03-2.33%
6 Months1.781.820.991.38265,238-0.52-29.21%
1 Year1.782.040.991.55376,415-0.52-29.21%
3 Years17.6323.6390.68012.98961,661-16.37-92.85%
5 Years6.7523.6390.68013.69627,103-5.49-81.33%

Spero Therapeutics Description

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |